Zhang Junying, Yin Li, Wu Jianzhong, Zhang Ye, Xu Tao, Ma Rong, Cao Haixia, Tang Jinhai
Department of Oncology, Xuzhou Medical College, Xuzhou, Jiangsu 221004, P.R. China.
Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, P.R. China.
Exp Ther Med. 2014 Jul;8(1):175-180. doi: 10.3892/etm.2014.1685. Epub 2014 Apr 14.
The aim of the present study was to assess the effect of the combined detection of serum vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) by Luminex multiplexed assays for the diagnosis, treatment and prognosis of breast cancer. Preoperative levels of serum VEGF and MMP-9 were detected via a lipid chip-based method in 301 breast cancer cases, 83 breast fibroadenoma cases and 40 healthy adults. Postoperative levels of VEGF and MMP-9 were also detected in 118 breast cancer cases. The levels of serum VEGF and MMP-9 in patients with breast infiltrative ductal carcinoma (IDC) were higher than those in the breast fibroadenoma and healthy control groups (P<0.05); there was no statistically significant difference between the breast fibroadenoma and healthy groups (P>0.05). The levels of VEGF and MMP-9 were shown to correlate with the clinical stage, tumor size and the lymph node metastasis status. However, the levels were not associated with age or gender (P>0.05). In addition, the serum level of MMP-9 exhibited a significantly correlation with the VEGF level (r=0.601, P<0.001). Subgroup analysis revealed that in patients with IDC, serum levels of VEGF and MMP-9 prior to surgery were significantly higher than those following surgery (P<0.05). Therefore, the serum levels of VEGF and MMP-9 can be used as markers for the diagnosis of breast IDC and may also be valuable for the prediction of lymph nodes metastasis.
本研究旨在评估采用Luminex多重检测法联合检测血清血管内皮生长因子（VEGF）和基质金属蛋白酶-9（MMP-9）对乳腺癌诊断、治疗及预后的影响。采用基于脂质芯片的方法检测了301例乳腺癌患者、83例乳腺纤维瘤患者及40例健康成年人术前血清VEGF和MMP-9水平。还检测了118例乳腺癌患者术后VEGF和MMP-9水平。乳腺浸润性导管癌（IDC）患者血清VEGF和MMP-9水平高于乳腺纤维瘤组和健康对照组（P<0.05）；乳腺纤维瘤组与健康组之间差异无统计学意义（P>0.05）。VEGF和MMP-9水平与临床分期、肿瘤大小及淋巴结转移状态相关。然而，其水平与年龄或性别无关（P>0.05）。此外，血清MMP-9水平与VEGF水平呈显著相关（r=0.601，P<0.001）。亚组分析显示，在IDC患者中，术前血清VEGF和MMP-9水平显著高于术后（P<0.05）。因此，血清VEGF和MMP-9水平可作为乳腺IDC诊断的标志物，对预测淋巴结转移也可能具有重要价值。
